<DOC>
	<DOCNO>NCT01877837</DOCNO>
	<brief_summary>This protocol investigate use stem cell transplantation , related donor , cure sickle cell disease . Sickle cell disease recessive disorder cause point mutation result substitution valine glutamic acid sixth position B-chain hemoglobin . This lead sickling red blood cell many condition , hypoxia , dehydration , hyperthermia . The sickling lead vaso-occlusion , cause irreversible damage almost system body , include central nervous system ( CNS ) , lung , heart , bone , eye , liver , kidney .</brief_summary>
	<brief_title>Stem Cell Transplantation Sickle Cell Anemia</brief_title>
	<detailed_description>Primary objective : 1 ) To determine disease free survival ( DFS ) one year match sibling transplant use either bone marrow ( BM ) , peripheral blood stem cell ( PBSC ) , umbilical cord blood ( UCB ) condition regimen consist Alemtuzumab , Fludarabine , Melphalan patient 2-30 y/o Secondary objective : 1 . Overall survival 2 . Rate neutrophil platelet engraftment BM vs. UCB 3 . Incidence graft failure 4 . Incidence grade II-IV grade III-IV acute graft v host disease ( GVHD ) 5 . Incidence chronic GVHD 6 . Incidence transplant complication , veno-occlusive disease , central nervous system ( CNS ) toxicity , idiopathic pneumonia syndrome ( IPS ) 7 . Incidence reactivation CMV , EBV , adenovirus , BK/JC virus 8 . Incidence invasive fungal disease 9 . Time immune reconstitution via monitoring lymphocyte subpopulation immunoglobulin level</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient Eligibility 1 ) Matched sibling donor ( 910/10 marrow/PBSC 56/6 UCB ( single double ) total TNC dose great 5 x 107/kg recipient weight ) 1 . Age 230 2 . Hb SS , Sthal0 , Sthal+ , SC 3 . Evidence ongoing hemolysis : Hb &lt; 10 , retic &gt; 5 % , LDH &gt; 500 , TB &gt; 2 4 . Karnofsky/Lansky score &gt; 50 5 . LVSF &gt; 26 % LVEF &gt; 40 % 6 . DLCO &gt; 40 % O2 sit &gt; 85 % patient ca n't perform PFTs 7 . GFR &gt; 70 serum creatinine &lt; 1.5 * ULN age 8 . ALT AST &lt; 5 x ULN , direct bilirubin &lt; 2 x ULN 9 . If patient chronic transfusion ferritin &gt; 1000 , liver biopsy do show evidence bridge fibrosis cirrhosis Exclusion criterion 1 . Evidence uncontrolled bacterial , viral , fungal infection within one month prior initiation condition regimen 2 . Pregnant breastfeed 3 . HIV positive 4 . Written inform consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stem cell transplant</keyword>
	<keyword>Sickle cell</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Related</keyword>
	<keyword>Unrelated</keyword>
</DOC>